

SUPPLEMENTARY TABLE 2. Association of immunocompromise and vaccination status* with in-hospital death among patients hospitalized for COVID-19, by SARS-CoV-2 variant predominant period[†] — COVID-NET, 10 States,[§] March 1, 2020–February 28, 2022

Comparison groups	aOR of in-hospital death (95% CI) by SARS-CoV-2 variant predominant period		
	Pre-Delta	Delta	Omicron
Immunocompromised versus nonimmunocompromised			
Unvaccinated [¶]	1.37 (1.02-1.82)**	1.31 (0.74-2.30)	1.04 (0.57-1.91)
Vaccinated ^{*,††}	2.91 (1.69-5.02) ^{§§}	2.51 (1.30-4.83) ^{§§}	0.99 (0.61-1.63)
Vaccinated versus unvaccinated*			
Immunocompromised ^{¶¶}	1.76 (0.82-3.75)	1.23 (0.57-2.64)	1.09 (0.44-2.72)
Nonimmunocompromised ^{***}	0.44 (0.23-0.84)**	0.42 (0.28-0.64) ^{§§}	0.84 (0.46-1.57)

Abbreviations: aOR, adjusted odds ratio; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network.

* Vaccinated patient: Patients with a positive SARS-CoV-2 test collected ≥ 14 days after either the second dose of a 2-dose vaccination series or after one dose of a single dose vaccine. When not otherwise specified, vaccinated patients include those who might have received additional or booster doses. Vaccinated patients without additional or booster doses include both those eligible and not yet eligible for an additional or booster dose. Vaccinated patients with additional booster doses are patients who have received additional or booster doses on or after August 13, 2021, with a positive SARS-CoV-2 test collected ≥ 14 days after receipt of additional or booster doses.

[†] Pre-Delta period, March 1, 2020–June 26, 2021; Delta period, June 27–December 18, 2021; Omicron period December 19, 2021–February 28, 2022 (Available at: <https://www.cdc.gov/mmwr/volumes/71/wr/mm7116e1.htm>)

[§] Selected counties in California, Colorado, Connecticut, Georgia, Michigan, Minnesota, New Mexico, New York, Oregon, and Tennessee

[¶] Model adjusted for age, sex, site, race/ethnicity (American Indian or Alaska Native and Asian or Pacific Islander were reclassified as other/unknown due to small numbers as well as patients who identified as multiracial or unknown race), long-term care facility, hypertension, diabetes, chronic lung disease, cardiovascular disease, renal disease, blood disorders, neurologic disease, and rheumatologic/ autoimmune disease. Death outcome unknown for one immunocompromised patient and 38 nonimmunocompromised patients.

** p-value <0.05

^{††} Model adjusted for age, sex, site, race/ethnicity (American Indian or Alaska Native and Asian or Pacific Islander were reclassified as other/unknown due to small numbers as well as patients who identified as multiracial or unknown race), cardiovascular disease, renal disease, and rheumatologic/autoimmune disease. Death outcome unknown for one immunocompromised patient and seven nonimmunocompromised patients.

^{§§} p-value <0.01

^{¶¶} Model adjusted for age, sex, site, variant predominant period, hypertension, renal disease, and rheumatologic/autoimmune conditions. Death outcome not known for one unvaccinated patient and one vaccinated patient without additional or booster doses.

^{***} Model adjusted for age, sex, site, variant predominant period, long term care facility residence, hypertension, diabetes mellitus, chronic metabolic disease, cardiovascular disease, renal disease, and neurologic disease. Death outcome among not known for 11 unvaccinated patients, three patients vaccinated without additional or booster doses, and three patients vaccinated with additional or booster doses.